Clinical studies have established immune checkpoint inhibitors targeting the programmed cell death‐1 (PD‐1)/PD‐1 ligand 1 (PD‐L1) axis as standard therapeutic regimens for patients with nonsmall cell lung cancer (NSCLC); however, around 70% patients have no objective response to PD‐1/PD‐L1 checkpoint blockade therapy.2, 3. This evidence concerns the gene CD274 and non-small cell lung carcinoma.